The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
2022
-
Randomized Controlled Trial Multicenter Study
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Nuvaxoid is safe and 90% effective against the Alpha (B.1.1.7) SARS-CoV-2 variant.
pearl -
Randomized Controlled Trial Multicenter Study
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ⋯ Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19. (Funded by Merck Sharp and Dohme; MOVe-OUT ClinicalTrials.gov number, NCT04575597.).